Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression

NCT03044249 is registered in ClinicalTrials.gov with Mediti Pharma Inc. as lead sponsor.

NCT NCT03044249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03044249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression
Lead sponsor
Mediti Pharma Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 4, 2017
Completion date
January 30, 2020
Enrollment
81 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

aggression, agitation, alzheimer dementia, dementia, psychosis